Next Article in Journal
3D-Printed Veterinary Dosage Forms—A Comparative Study of Three Semi-Solid Extrusion 3D Printers
Next Article in Special Issue
Rational Vaccine Design in Times of Emerging Diseases: The Critical Choices of Immunological Correlates of Protection, Vaccine Antigen and Immunomodulation
Previous Article in Journal
Solubility, Permeability, and Dissolution Rate of Naftidrofuryl Oxalate Based on BCS Criteria
Article

Applying Microfluidics for the Production of the Cationic Liposome-Based Vaccine Adjuvant CAF09b

1
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK
2
Department of Infectious Disease Immunology, Center for Vaccine Research, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark
*
Authors to whom correspondence should be addressed.
Pharmaceutics 2020, 12(12), 1237; https://doi.org/10.3390/pharmaceutics12121237
Received: 29 October 2020 / Revised: 16 December 2020 / Accepted: 16 December 2020 / Published: 19 December 2020
Subunit vaccines require particulate adjuvants to induce the desired immune responses. Pre-clinical manufacturing methods of adjuvants are often batch dependent, which complicates scale-up for large-scale good manufacturing practice (GMP) production. The cationic liposomal adjuvant CAF09b, composed of dioctadecyldimethylammonium bromide (DDA), monomycoloyl glycerol analogue 1 (MMG) and polyinosinic:polycytidylic acid [poly(I:C)], is currently being clinically evaluated in therapeutic cancer vaccines. Microfluidics is a promising new method for large-scale manufacturing of particle-based medicals, which is scalable from laboratory to GMP production, and a protocol for production of CAF09b by this method was therefore validated. The influence of the manufacture parameters [Ethanol] (20–40% v/v), [Lipid] (DDA and MMG, 6–12 mg/mL) and dimethyl sulfoxide [DMSO] (0–10% v/v) on the resulting particle size, colloidal stability and adsorption of poly(I:C) was evaluated in a design-of-experiments study. [Ethanol] and [DMSO] affected the resulting particle sizes, while [Lipid] and [DMSO] affected the colloidal stability. In all samples, poly(I:C) was encapsulated within the liposomes. At [Ethanol] 30% v/v, most formulations were stable at 21 days of manufacture with particle sizes <100 nm. An in vivo comparison in mice of the immunogenicity to the cervical cancer peptide antigen HPV-16 E7 adjuvanted with CAF09b prepared by lipid film rehydration or microfluidics showed no difference between the formulations, indicating adjuvant activity is intact. Thus, it is possible to prepare suitable formulations of CAF09b by microfluidics. View Full-Text
Keywords: subunit vaccine; liposome; microfluidics subunit vaccine; liposome; microfluidics
Show Figures

Figure 1

MDPI and ACS Style

Schmidt, S.T.; Christensen, D.; Perrie, Y. Applying Microfluidics for the Production of the Cationic Liposome-Based Vaccine Adjuvant CAF09b. Pharmaceutics 2020, 12, 1237. https://doi.org/10.3390/pharmaceutics12121237

AMA Style

Schmidt ST, Christensen D, Perrie Y. Applying Microfluidics for the Production of the Cationic Liposome-Based Vaccine Adjuvant CAF09b. Pharmaceutics. 2020; 12(12):1237. https://doi.org/10.3390/pharmaceutics12121237

Chicago/Turabian Style

Schmidt, Signe T., Dennis Christensen, and Yvonne Perrie. 2020. "Applying Microfluidics for the Production of the Cationic Liposome-Based Vaccine Adjuvant CAF09b" Pharmaceutics 12, no. 12: 1237. https://doi.org/10.3390/pharmaceutics12121237

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop